{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:57:54Z","timestamp":1772348274325,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neurol.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T21:19:13Z","timestamp":1663708753000},"page":"30-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treating hereditary transthyretin amyloidosis: Present & future challenges"],"prefix":"10.1016","volume":"179","author":[{"given":"A.","family":"Echaniz-Laguna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cauquil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Labeyrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.07.006_bib0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2022.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.neurol.2022.07.006_bib0085","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.jacc.2015.08.870","article-title":"Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis","volume":"66","author":"Algalarrondo","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.neurol.2022.07.006_bib0090","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.07.006_bib0095","unstructured":"https:\/\/www.nice.org.uk\/guidance\/ta696\/chapter\/1-Recommendations."},{"key":"10.1016\/j.neurol.2022.07.006_bib0100","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03860935."},{"key":"10.1016\/j.neurol.2022.07.006_bib0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.07.006_bib0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.07.006_bib0115","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.neurol.2022.07.006_bib0120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.07.006_bib0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.07.006_bib0130","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jnc.15233","article-title":"Targeting transthyretin mechanism-based treatment approaches and future perspectives in hereditary amyloidosis","volume":"156","author":"Dohrn","year":"2021","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2022.07.006_bib0135","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.0000000000012965","article-title":"CNS involvement in hereditary transthyretin amyloidosis","volume":"97","author":"Sousa","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.07.006_bib0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s42466-021-00155-8","article-title":"Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis","volume":"3","author":"Dohrn","year":"2021","journal-title":"Neurol Res Pract"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:06Z","timestamp":1758519966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722007421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":14,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0035378722007421"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.07.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating hereditary transthyretin amyloidosis: Present & future challenges","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}